Patent ID: 8206708
Filing Date: 2012-06-26
Classification: A01K,A61K,A61P,C07K,C12N,G01N,Y02A,Y10S

Abstract:
1. A method of treating corneal neovascularization in a human subject, comprising administering to the eye of the human subject an effective amount of an isolated antibody or antigen binding fragment thereof that specifically binds a human Vascular Endothelial Growth Factor-2 (VEGF-2) polypeptide, wherein the administering results in inhibition of the formation of new blood vessels in the human subject, and wherein the antibody or antigen binding fragment thereof comprises: (a) a first amino acid sequence that is at least 99% identical to the amino acid sequence of the VH domain of the antibody expressed by the hybridoma cell line deposited under ATCC Deposit No. PTA-4095, wherein the first amino acid sequence comprises the amino acid sequences of the VHCDR1, VHCDR2, and VHCDR3 regions of the antibody expressed by the hybridoma deposited under ATCC Deposit No. PTA-4095; and (b) a first amino acid sequence that is at least 99% identical to the amino acid sequence of the VH domain of the 69D09 ScFv shown in SEQ ID NO:79, wherein the first amino acid sequence comprises: a VHCDR1 consisting of the amino acid sequence of amino acid residues 26-35 of SEQ ID NO:79; a VHCDR2 consisting of the amino acid sequence of amino acid residues 50-66 of SEQ ID NO:79; and a VHCDR3 consisting of the amino acid sequence of amino acid residues 99-107 of SEQ ID NO:79; and